Literature DB >> 20121412

Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency.

C L Gordon1, P D R Johnson, M Permezel, N E Holmes, G Gutteridge, C F McDonald, D P Eisen, A J Stewardson, J Edington, P G P Charles, N Crinis, M J Black, J Torresi, M L Grayson.   

Abstract

BACKGROUND: . Severe pandemic 2009 influenza A virus (H1N1) infection is associated with risk factors that include pregnancy, obesity, and immunosuppression. After identification of immunoglobulin G(2) (IgG(2)) deficiency in 1 severe case, we assessed IgG subclass levels in a cohort of patients with H1N1 infection.
METHODS: Patient features, including levels of serum IgG and IgG subclasses, were assessed in patients with acute severe H1N1 infection (defined as infection requiring respiratory support in an intensive care unit), patients with moderate H1N1 infection (defined as inpatients not hospitalized in an intensive care unit), and a random sample of healthy pregnant women.
RESULTS: Among the 39 patients with H1N1 infection (19 with severe infection, 7 of whom were pregnant; 20 with moderate infection, 2 of whom were pregnant), hypoabuminemia (P < .001), anemia (P < .001), and low levels of total IgG (P= .01), IgG(1) (P= .022), and IgG(2) (15 of 19 vs 5 of 20; P= .001; mean value +/- standard deviation [SD], 1.8 +/- 1.7 g/L vs 3.4 +/- 1.4 g/L; P= .003) were all statistically significantly associated with severe H1N1 infection, but only hypoalbuminemia (P= .02) and low mean IgG(2) levels (P= .043) remained significant after multivariate analysis. Follow-up of 15 (79%) surviving IgG(2)-deficient patients at a mean (+/- SD) of 90 +/- 23 days (R, 38-126) after the initial acute specimen was obtained found that hypoalbuminemia had resolved in most cases, but 11 (73%) of 15 patients remained IgG(2) deficient. Among 17 healthy pregnant control subjects, mildly low IgG(1) and/or IgG(2) levels were noted in 10, but pregnant patients with H1N1 infection had significantly lower levels of IgG(2) (P= .001).
CONCLUSIONS: Severe H1N1 infection is associated with IgG(2) deficiency, which appears to persist in a majority of patients. Pregnancy-related reductions in IgG(2) level may explain the increased severity of H1N1 infection in some but not all pregnant patients. The role of IgG(2) deficiency in the pathogenesis of H1N1 infection requires further investigation, because it may have therapeutic implications.

Entities:  

Mesh:

Year:  2010        PMID: 20121412     DOI: 10.1086/650462

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  42 in total

1.  The lower serum immunoglobulin G2 level in severe cases than in mild cases of pandemic H1N1 2009 influenza is associated with cytokine dysregulation.

Authors:  Jasper Fuk-Woo Chan; Kelvin Kai-Wang To; Herman Tse; Candy Choi-Yi Lau; Iris Wai-Sum Li; Ivan Fan-Ngai Hung; Kwok-Hung Chan; Vincent Chi-Chung Cheng; Thomas Sik-To Lai; Patrick Chiu-Yat Woo; Eric Yuk-Tat Chan; Kwok-Yung Yuen
Journal:  Clin Vaccine Immunol       Date:  2010-12-01

2.  Challenges in HSV encephalitis: normocellular CSF, unremarkable CCT, and atypical MRI findings.

Authors:  Jan Philipp Bewersdorf; Uwe Koedel; Maximilian Patzig; Konstantinos Dimitriadis; Grit Paerschke; Hans-Walter Pfister; Matthias Klein
Journal:  Infection       Date:  2018-12-01       Impact factor: 3.553

3.  Fatal outcome of pandemic H1N1 2009 influenza virus infection is associated with immunopathology and impaired lung repair, not enhanced viral burden, in pregnant mice.

Authors:  Glendie Marcelin; Jerry R Aldridge; Susu Duan; Hazem E Ghoneim; Jerold Rehg; Henju Marjuki; Adrianus C M Boon; Jonathan A McCullers; Richard J Webby
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

4.  Use of intravenous immunoglobulin in critically ill patients.

Authors:  Summer Donovan; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

5.  Immunoglobulin G subclass levels and antibody responses to the 2009 influenza A (H1N1) monovalent vaccine among human immunodeficiency virus (HIV)-infected and HIV-uninfected adults.

Authors:  N F Crum-Cianflone; G Collins; G Defang; E Iverson; L E Eberly; C Duplessis; J Maguire; A Ganesan; B K Agan; T Lalani; T Whitman; C Brandt; D Faix; P J Blair; T Burgess
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

Review 6.  Influenza immunization during pregnancy: Benefits for mother and infant.

Authors:  Isaac G Sakala; Yoshikazu Honda-Okubo; Johnson Fung; Nikolai Petrovsky
Journal:  Hum Vaccin Immunother       Date:  2016-08-05       Impact factor: 3.452

Review 7.  Influenza, immune system, and pregnancy.

Authors:  Renju S Raj; Elizabeth A Bonney; Mark Phillippe
Journal:  Reprod Sci       Date:  2014-06-04       Impact factor: 3.060

Review 8.  Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies.

Authors:  Kathleen E Sullivan; Hamid Bassiri; Ahmed A Bousfiha; Beatriz T Costa-Carvalho; Alexandra F Freeman; David Hagin; Yu L Lau; Michail S Lionakis; Ileana Moreira; Jorge A Pinto; M Isabel de Moraes-Pinto; Amit Rawat; Shereen M Reda; Saul Oswaldo Lugo Reyes; Mikko Seppänen; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2017-08-07       Impact factor: 8.317

9.  Wild type and mutant 2009 pandemic influenza A (H1N1) viruses cause more severe disease and higher mortality in pregnant BALB/c mice.

Authors:  Kwok-Hung Chan; Anna J X Zhang; Kelvin K W To; Chris C S Chan; Vincent K M Poon; Kunyuan Guo; Fai Ng; Qi-Wei Zhang; Virtual H C Leung; Annie N Y Cheung; Candy C Y Lau; Patrick C Y Woo; Herman Tse; Wailan Wu; Honglin Chen; Bo-Jian Zheng; Kwok-Yung Yuen
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

10.  Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine.

Authors:  Karen K Yam; Jyotsana Gupta; Angela Brewer; David W Scheifele; Scott Halperin; Brian J Ward
Journal:  Clin Vaccine Immunol       Date:  2013-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.